Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1β release in vitro and ex vivo [1]

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 3, 2003, Pages 272-274

  Wagner, Irmela ^a   Greim, Cornelia ^a   Laufer, Stefan ^a   Heide, Lutz ^a   Gleiter, Christoph H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; HARPAGOPHYTUM EXTRACT; INTERLEUKIN 1BETA; PLANT EXTRACT; PROSTAGLANDIN E2; SALIX DAPHNOIDES EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BARK; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LETTER; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WILLOW;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; BENZYL ALCOHOLS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-1; ISOENZYMES; MEMBRANE PROTEINS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REFERENCE VALUES; RHEUMATIC DISEASES; SALIX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037373656     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.32     Document Type: Letter

References (13)

1. Blumenthal M, editor. The complete German Commission E monographs. Austin (TX): American Botanical Council; 1998. p. 120-1, 230.
2. Schmid B, Lüdtke R, Selbmann HK, et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res 2001;15:344-50.
3. Chrubasik S, Eisenberg E, Balan E, et al. Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. Am J Med 2000;109:9-14.
4. Chrubasik S, Künzel O, Model A, Conradt C, Black A. Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology (Oxford) 2001;40:1388-93.
5. Schmid B, Kötter I, Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur J Clin Pharmacol 2001;57:387-91.
6. Chrubasik S. Weidenrindenextrakt. Deutsche Apotheker Zeitung 2000;140:3825-7.
7. Chrubasik S. Pollak S. Schmerzbehandlung mit pflanzlichen Antirheumatika. Wien Med Wochenschr 2002;152:198-203.
8. März RW, Kemper F. Weidenrindenextrakt - Wirkungen und Wirksamkeit. Erkenntnisstand zu Pharmakologie, Toxikologie und Klinik. Wien Med Wochenschr 2002;152:354-9.
9. Laufer S, Striegel HG, Neher K, et al. Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors. Arch Pharm (Weinheim) 1997;330:307-12.
10. Laufer S, Zechmeister P, Klein T. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors. Inflamm Res 1999;48:133-8.
11. Laufer SA, Wagner GK. From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem 2002;45:2733-40.
12. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563-8.
13. Loew D, Möllerfeld J, Schrödter A, Puttkammer S, Kaszkin M. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 2001;69:356-64.